Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?

被引：5

作者：

Pal, Sumanta ^{[1
]}

Hu-Lieskovan, Siwen ^{[2
]}

Agarwal, Neeraj ^{[2
]}

机构：

[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA 91010 USA

[2] Univ Utah, Div Med Oncol, Huntsman Canc Inst, Salt Lake City, UT USA

来源：

LANCET ONCOLOGY | 2019年 / 20卷 / 11期

关键词：

NIVOLUMAB;

D O I：

10.1016/S1470-2045(19)30619-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1473 / 1474

页数：2

共 50 条

[31] PEGylated human IL-10 (AM0010) in combination with pembrolizumab in anti-PD1 and CTLA-4 refractory melanoma.
Naing, Aung
Wong, Deborah Jean Lee
Infante, Jeffrey R.
Patel, Manish R.
Pant, Shubham
Chmielowski, Bartosz
Janku, Filip
Tapia, Coya
Ratti, Navneet
Van Vlasselaer, Peter
Brown, Gail Linda
Hung, Annie
Oft, Martin
Diab, Adi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[32] Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
Naing, Aung
Pant, Shubham
Infante, Jeffrey
Papadopoulos, Kyriakos
Autio, Karen
Wong, Deborah
Ott, Patrick
Falchook, Gerald
Patel, Manish
Whiteside, Melinda
Colen, Rivka
Bendell, Johanna
Bauer, Todd
Janku, Filip
Javle, Milind
Tannir, Nixar
Oft, Martin
Chan, Ivan
Rasco, Drew
Hong, David
Patnaik, Amita
Moore, Kathen
Korn, Michael
Van-Vlasselaer, Peter
Brown, Gail
BJU INTERNATIONAL, 2016, 118 : 25 - 25
[33] Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
Naing, A.
Papadopoulos, K. P.
Autio, K. A.
Ott, P. A.
Patel, M. R.
Wong, D. J.
Falchook, G.
Pant, S.
Whiteside, M.
Rasco, D.
Patnaik, A.
Bendell, J. C.
Bauer, T. M.
Colen, R. R.
Hong, D.
Van Vlasselaer, P.
Brown, G. L.
Oft, M.
Tannir, N.
Infante, J. R.
ANNALS OF ONCOLOGY, 2016, 27
[34] Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC.
Wong, Deborah Jean Lee
Schneider, Jeffrey Gary
Aljumaily, Raid
Korn, Wolfgang Michael
Infante, Jeffrey R.
Patel, Manish R.
Autio, Karen A.
Papadopoulos, Kyriakos P.
Naing, Aung
Gabrail, Nashat Y.
Munster, Pamela N.
Goldman, Jonathan Wade
Van Vlasselaer, Peter
Brown, Gail Linda
Hung, Annie
Oft, Martin
Garon, Edward B.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35] Activation of PD-1 Protects Intestinal Immune Defense Through IL-10/miR-155 Pathway After Intestinal Ischemia Reperfusion
Xu-Yu Zhang
Su Guan
Hu-Fei Zhang
Rui-Yun Li
Zi-Meng Liu
Digestive Diseases and Sciences, 2018, 63 : 3307 - 3316
[36] PD-1, IL-10 and IFN-γ form a network to regulate HIV-specific CD4 T cell dysfunction
Porichis, Filippos
Kwon, Douglas
Jennifer, Zupkosky
Hart, Meghan
McMullen, Ashley
Freeman, Gordon
Kavanagh, Daniel
Kaufmann, Daniel
JOURNAL OF IMMUNOLOGY, 2012, 188
[37] Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors
Infante, Jeffrey R.
Naing, Aung
Papadopoulos, Kyriakos P.
Autio, Karen A.
Ott, Patrick A.
Wong, Deborah J.
Falchook, Gerald S.
Patel, Manish
Pant, Shubham
Whiteside, Melinda
Mumm, John B.
Chan, Ivan H.
Bendell, Johanna C.
Bauer, Todd M.
Janku, Filip
Javle, Milind
Colen, Rivka R.
Tannir, Nizar M.
Oft, Martin
CANCER RESEARCH, 2016, 76
[38] Combined blockade of the PD-1 and IL-10 pathways synergistically enhance HIV-specific CD4 T cell functions
Porichis, F.
Kwon, D. S.
Tighe, D. P.
Pavlik, D. F.
Kavanagh, D. G.
Freeman, G. J.
Walker, B. D.
Kaufmann, D. E.
RETROVIROLOGY, 2009, 6
[39] Activation of PD-1 Protects Intestinal Immune Defense Through IL-10/miR-155 Pathway After Intestinal Ischemia Reperfusion
Zhang, Xu-Yu
Guan, Su
Zhang, Hu-Fei
Li, Rui-Yun
Liu, Zi-Meng
DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (12) : 3307 - 3316
[40] The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia
Jimbu, Laura
Mesaros, Oana
Neaga, Alexandra
Nanut, Ana Maria
Tomuleasa, Ciprian
Dima, Delia
Bocsan, Corina
Zdrenghea, Mihnea
PHARMACEUTICALS, 2021, 14 (11)

← 1 2 3 4 5 →